GlassScriptPhysician profile
David John Pengilly
NPI 1710099114
$8,085.47
in general payments reported to CMS, 2019-2025
38 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $641 · 2021: $307 · 2022: $1,209 · 2023: $1,521 · 2024: $1,605 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,128.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,039.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $982.77 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $875.18 | 2019-2025 | |
| Novo Nordisk INC | $815.39 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $814.80 | 2021-2025 | |
| Astellas Pharma US INC | $418.93 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $270.04 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $250.54 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.83 | 2019-2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $123.57 | 2021-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $107.77 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $100.13 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $90.71 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pengilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.